Elizabeth Kolawole
Family Medicine · Trinity, FLNPI 1194222455
Payments from drug & device makers
Across 61 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$547
- GSK$228
- AbbVie$198
- Gilead$175
- Neurocrine Biosciences, Inc.$165
- Amgen$146
- plus $371 from 14 others
What the payments were for
- Food & beverage$1,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 1 | $547 |
| GSK | 8 | $228 |
| AbbVie | 11 | $198 |
| Gilead | 9 | $175 |
| Neurocrine Biosciences, Inc. | 7 | $165 |
| Amgen | 2 | $146 |
| Teva Pharmaceuticals USA, Inc. | 4 | $66 |
| Hologic Sales And Service, LLC | 3 | $59 |
| Pfizer | 2 | $38 |
| Lilly USA, LLC | 2 | $30 |
| Dexcom, Inc. | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $25 |
| Phadia US Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Cranial Technologies, Inc | 1 | $15 |
| AstraZeneca | 1 | $14 |
| Fisher Scientific Company L.L.C. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$125
How this compares
$1,832 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $31,242 |
| JardianceEmpagliflozin | 24 | $25,016 |
| TrulicityDulaglutide | 24 | $23,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $14,228 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $10,140 |
| JanuviaSitagliptin Phosphate | 12 | $6,814 |
| Ventolin HfaAlbuterol Sulfate | 49 | $2,574 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,549 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $2,127 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,960 |
| Levetiracetam | 25 | $1,348 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 13 | $876 |
| Atorvastatin Calcium | 81 | $744 |
| Gabapentin | 44 | $583 |
| Losartan Potassium | 77 | $582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $30 | $23,85224 claims |
| GSKTrelegy Ellipta | $228 | $14,22812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Trinity
- Cathy BarnesTrinity$11.3M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.